^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF mutation

    i
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer (NCT03841617)
    Phase 2
    National Institute of Diabetes and Digestive an...
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/29/2019
    Primary completion :
    02/01/2030
    Completion :
    02/01/2030
    BRAF • TG
    |
    BRAF mutation
    SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma (NCT04923126)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/21/2021
    Primary completion :
    06/01/2031
    Completion :
    06/01/2031
    BRAF • NF1 • PTPN11 • MYBL1
    |
    BRAF mutation
    |
    Gomekli (mirdametinib)
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (NCT04119024)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2019
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (NCT01950390)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/24/2014
    Primary completion :
    10/06/2021
    Completion :
    01/31/2026
    BRAF
    |
    BRAF mutation • BRAF wild-type
    |
    Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • CS1002 (ipilimumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (NCT02339571)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/23/2015
    Primary completion :
    06/30/2033
    Completion :
    06/30/2033
    BRAF
    |
    BRAF mutation • BRAF wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Leukine (sargramostim)
    Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer (NCI-2021-11793) (NCT05111561)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/21/2025
    Initiation :
    08/02/2022
    Primary completion :
    03/14/2025
    Completion :
    03/14/2025
    HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1
    |
    BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion
    |
    Mektovi (binimetinib) • ZEN-3694
    Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (NCT05078866)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/10/2022
    Primary completion :
    07/31/2025
    Completion :
    07/31/2025
    BRAF • MSI • MLH1 • MSH6 • MSH2
    |
    BRAF mutation
    |
    NOUS-209
    A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer (NAUTIKA1) (NCT04302025)
    Phase 2
    Genentech, Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/06/2020
    Primary completion :
    12/30/2025
    Completion :
    03/06/2029
    PD-L1 • KRAS • BRAF • ALK • RET • ROS1 • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • BRAF mutation • BRAF V600 • RET fusion • ALK fusion • RET mutation • ROS1 fusion • KRAS G12
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Cotellic (cobimetinib) • Gavreto (pralsetinib) • divarasib (RG6330)
    Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations (NCT06043713)
    Phase 1
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    12/15/2023
    Primary completion :
    12/31/2025
    Completion :
    02/09/2026
    HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK
    |
    KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion
    |
    cyclophosphamide • bendamustine • fludarabine IV
    Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (NCT05554328)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    04/25/2023
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    Lynparza (olaparib) • Koselugo (selumetinib)
    ACT-TIL and ANV419 for Advanced Melanoma. (BaseTIL-03M) (NCT05869539)
    Phase 1
    University Hospital, Basel, Switzerland
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    06/21/2023
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    ANV419
    A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors (SGNBB228-001) (NCT05571839)
    Phase 1
    Seagen, a wholly owned subsidiary of Pfizer
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    01/03/2023
    Primary completion :
    04/19/2027
    Completion :
    04/18/2028
    BRAF
    |
    BRAF mutation
    |
    PF-08046049
    Safety and Efficacy of OBX-115 in Advanced Solid Tumors (Agni-01) (NCT06060613)
    Phase 1/2
    Obsidian Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/25/2023
    Primary completion :
    10/30/2025
    Completion :
    10/30/2027
    PD-L1 • BRAF • PD-1
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • OBX-115
    Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies (NCT04181788)
    Phase 2
    Pfizer
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    03/18/2020
    Primary completion :
    03/03/2022
    Completion :
    04/30/2025
    EGFR • PD-L1 • BRAF • ALK • ROS1
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
    |
    sasanlimab (PF-06801591)
    A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) (NCT05099003)
    Phase 1/2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/18/2025
    Initiation :
    05/31/2022
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    BRAF • IDH1
    |
    BRAF mutation • BRAF V600 • IDH1 mutation
    |
    Xpovio (selinexor)
    A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (ST101-101) (NCT04478279)
    Phase 1/2
    Sapience Therapeutics
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/01/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF
    |
    HR positive • BRAF mutation
    |
    temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)
    TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (NCT05862324)
    Phase 1/2
    Triumvira Immunologics, Inc.
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    08/23/2023
    Primary completion :
    08/01/2027
    Completion :
    08/01/2027
    EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA
    |
    EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2
    Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) (NCT03669523)
    Phase 2
    Centre Hospitalier Annecy Genevois
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    11/06/2018
    Primary completion :
    10/19/2023
    Completion :
    10/19/2023
    EGFR • PD-L1 • BRAF • ALK
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
    |
    Opdivo (nivolumab) • Prolia (denosumab) • zoledronic acid
    A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) (KEYNOTE-F21) (NCT04225117)
    Phase 2
    Astellas Pharma Global Development, Inc.
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    03/09/2020
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    BRAF • ER • ALK • PGR
    |
    PD-L1 expression • HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER negative • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (SAKK 66/17) (NCT03993678)
    Phase 1/2
    Swiss Group for Clinical Cancer Research
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    10/12/2020
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    BRAF
    |
    BRAF mutation
    |
    IP-001
    Axitinib + Ipilimumab in Advanced Melanoma (NCT04996823)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    08/04/2021
    Primary completion :
    03/29/2026
    Completion :
    03/29/2027
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Yervoy (ipilimumab) • Inlyta (axitinib)
    A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma (NCT05943795)
    Phase 3
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK
    |
    KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion
    |
    docetaxel • izalontamab (SI-B001)
    Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer (NCT02188264)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    08/29/2014
    Primary completion :
    01/31/2017
    Completion :
    04/26/2019
    BRAF • RAF1 • MAPK1
    |
    BRAF mutation • RAS mutation
    |
    Koselugo (selumetinib) • cyclosporin A microemulsion
    PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/15/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
    |
    BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification
    |
    Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
    Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma (BNT111-01) (NCT04526899)
    Phase 2
    BioNTech SE
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    05/19/2021
    Primary completion :
    01/25/2024
    Completion :
    07/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Libtayo (cemiplimab-rwlc) • BNT111
    Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (NCT01701674)
    Phase N/A
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/09/2012
    Primary completion :
    04/21/2016
    Completion :
    09/08/2025
    BRAF
    |
    BRAF mutation • BRAF V600 • BRAF wild-type
    |
    Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous
    Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) (NCT03665597)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/10/2025
    Initiation :
    11/19/2018
    Primary completion :
    12/04/2023
    Completion :
    12/04/2023
    BRAF • TNFRSF9
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • MK-3475 SC
    A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) (NCT05512208)
    Phase 2
    University of Oklahoma
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/06/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2029
    BRAF • NF1 • RAS
    |
    BRAF mutation • RAS mutation
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma (NCT02721459)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    09/07/2016
    Primary completion :
    10/31/2019
    Completion :
    03/01/2025
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib) • XL888
    Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors (BGB-3245-AU-001) (NCT04249843)
    Phase 1
    MapKure, LLC
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/17/2020
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    KRAS • BRAF • NRAS
    |
    KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion
    |
    brimarefenib (BGB-3245)
    Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma (NCT05628883)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    11/22/2022
    Primary completion :
    12/01/2025
    Completion :
    12/31/2026
    BRAF • IL2
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • TIDAL-01
    Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (KEYNOTE B81) (NCT04609566)
    Phase 2
    Seagen Inc.
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    01/26/2021
    Primary completion :
    12/31/2025
    Completion :
    09/30/2026
    EGFR • BRAF • ALK • ROS1
    |
    EGFR mutation • BRAF mutation • ALK mutation
    |
    Keytruda (pembrolizumab) • Adcetris (brentuximab vedotin)
    Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (EA5163) (NCT03793179)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/05/2019
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    EGFR • PD-L1 • BRAF • ALK • ROS1
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)
    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT01708954)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/13/2013
    Primary completion :
    08/14/2015
    Completion :
    03/07/2025
    HER-2 • KRAS • BRAF • RET
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion
    |
    erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases (CAIRO5) (NCT02162563)
    Phase 3
    Dutch Colorectal Cancer Group
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    07/01/2014
    Primary completion :
    07/01/2022
    Completion :
    01/01/2025
    BRAF • RAS
    |
    BRAF mutation • RAS mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (C4901001) (NCT05538130)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/30/2022
    Primary completion :
    12/31/2027
    Completion :
    07/03/2029
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • claturafenib (PF-07799933)
    JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors (KEYNOTE-F62) (NCT06108050)
    Phase 1
    Jazz Pharmaceuticals
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    11/07/2023
    Primary completion :
    11/30/2027
    Completion :
    05/31/2028
    BRAF • MSI
    |
    MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • JZP898
    Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03213691)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    10/30/2017
    Primary completion :
    06/30/2021
    Completion :
    12/31/2024
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Koselugo (selumetinib)
    NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis (NCT04129515)
    Phase 1/2
    Brown University
    Not yet recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/30/2025
    Primary completion :
    03/01/2026
    Completion :
    01/01/2027
    BRAF
    |
    BRAF mutation • BRAF wild-type
    |
    Keytruda (pembrolizumab)
    Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) (NCT03839342)
    Phase 2
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    06/07/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF • KIAA1549
    |
    BRAF mutation • BRAF V600K • BRAF fusion
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer (NCT04420754)
    Phase 1
    AffyImmune Therapeutics, Inc.
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    09/28/2020
    Primary completion :
    08/04/2026
    Completion :
    08/04/2030
    BRAF • ICAM1
    |
    BRAF mutation • BRAF wild-type
    |
    AIC100